Table 5.

Characteristics of the positive rechallenge cases.

Sex			Age (years)		Medical history		Vertigo		Tinnitus		Vaccination rank and delay onset (days)		Hearing loss side		Hearing loss gradea		Final hearing recovery
Tozinameran
	Female	61		None		Yes		Yes		D1b—4 D2c—7 Bd—7		Unilateral		3		No improvement
	Male	47		None		No		Yes		D1—9 D2—9		Unilateral		3		No improvement
	Female	74		Fluctuating hearing loss and vertigo punctually treated with steroids		No		Yes		D1—8 D2—9		Unilateral		3		Complete recovery
	Female	32		Protein S deficiency		No		No		D1—8 D2—2		Unilateral		2		Complete recovery
	Female	79		Diabetes mellitus stabilized since 1977, left Ménière’ disease since 1977, hypothyroidism stabilized, high blood pressure stabilized since 1985, and hypercholesterolemia stabilized since 1985		Yes		Yes		D1—8 D2—8 B—R-e		Unilateral (contralateral to the Ménière side)		2		Complete recovery
Elasomeran
	Female	45		None		No		Yes		D1—5 D2—<1 B—R-e		Bilateral		2		Complete recovery
	Male	71		None		No		Yes		D1—1 D2—1		Unilateral		2		Complete recovery
	Female	41		High blood pressure		No		Yes		D2—60 B—40		Bilateral		2		No improvement

^aMeasured after injection.

^bD1: first vaccine injection.

^cD2: second vaccine injection.

^dB: booster.

^eR-: Negative rechallenge (no recurrence of sudden sensorineural hearing loss; the booster of elasomeran was administered at half dose).